Abstract: This paper describes the conditions under which the aclacinomycin-A nanocapsules (ACM-A-NC) were prepared and lyophilized. These nanocapsules were also subjected to a redispersion test. Their size distribution and drug encapsulation efficiency were also determined. The drug concentrations in blood had shown that the aclacinomycin-A encapsulated in nanocapsules was released well after intravenous injection in rabbits. The data fit into an open two-compartment model. The rabbits given ACM-A-NC had a longer elimination half-life (t1/2(β) = 17.04 h)and a larger AUC (106.74 mg/L·h) than the group given ACM-A injection (t1/2(β) = 10.25h, AUC = 81.88 mg/L·h) Furthermore, the encapsulation of aclacinomycin-A in polybutylcyanoacrylate nanocapslues could change the drug distribution in rats, It was demonstrated that a higher level of ACM-A was found in the lung, thymus, spleen and small intestine while a lower level was found in the heart, kidney and large intestine.

Key words: Polybutylcyanoacrylate nanocapsules, Aclacinomycin-A, Pharmacokinetic parameter, Distribution patterns